The most effective treatment for adenocarcinoma is surgical resection, especially curative resection in patients with early-stage cancers. Radiation therapy is beneficial for locally advanced cancers and is recommended as first-line treatment for distant metastases; postoperative radiation therapy is often recommended as part of adjuvant treatment. Chemotherapy is used for advanced and unresectable cancers. In addition, there are several novel therapies in clinical trials to be evaluated for treatment of carcinoma.
Adenocarcinoma are a group of malignant neoplasms characterized by the presence of glandular structure or a mucin production. Mucin, as it is produced by the malignant cells, contributes to the tumor's invasive behavior. It is therefore conceivable that the mucin production in these neoplasms could favor distant metastasis. Anyway, the study of its pathogenesis requires further investigations, since these observations are not totally understood.
Adenocarcinoma presents as a mass. Non-mass lesions often occur and can be asymptomatic. In the setting of a history of alcohol or smoking, or symptoms of gastrointestinal or chest pain, it is extremely important to have an colonoscopy when detecting adenocarcinoma. Adenocarcinoma in this setting is usually adenocarcinoma of the colon with a good prognosis. As with the other gastrointestinal malignancies, the use of PET/CT scanning has allowed earlier detection of metastases to regional lymph nodes, liver, lung, or brain. The addition of CT scanning to standard evaluation may alter management in up to 25 % of cases.
Completely pure adenocarcinoma of the pancreas can be cured. When it coexists in an adenoma, cure is possible if adenocarcinoma has not expanded locally. If adenocarcinoma has expanded locally, recurrence is high.
Results from a recent paper was based on data collected by the National Cancer Institute in the USA, and reflects the current experience of clinicians and scientists in the US. However, the results and conclusions are applicable throughout the world. The National Cancer Institute estimates that in 2006 there are a total of 1,093,564 new cases, 2,064,664 deaths from the disease and more than 600,000 patients diagnosed with malignant tumors of the lung, breast and cervical/vaginal system.
Adenocarcinoma is a type of cancer that results when cells form in glandular or intestinal structures of the intestine. This cancer consists of cells that come from the lining of the digestive tract.\n
Adjunct therapies can be a powerful adjuvant for surgery to improve patient survival. Treatment usually consists of concurrent or sequential chemotherapy and/or radiotherapy. Surgical staging is commonly used to help identify patients at risk for metastatic disease. The exact role of surgical staging and multimodal therapies are not well understood. The best treatment strategy for metastatic PSC remains unclear. A multi-modal therapy with surgery, radio-chemotherapy, and adjuvant chemotherapy is recommended. Surgery should be performed to maximize local tumor control and prevent recurrence. Surgery is not curative but is an important component of treatment. As of right now, there are no effective adjuvant treatments for surgically treated PSC patients.
If the current clinical trials are not successful, new therapies may be developed in the future. The NCI has recently created a database of all recent clinical trials involving treatments for a variety of cancers. A clinical trial is in progress at the NCI Cancer Center. The NCI is also going to create a website to guide patients through treatments available for different types of cancer, such as small cell lung carcinoma.
The use of cetuximab and paclitaxel alone or paclitaxel plus carboplatin is not significantly different compared with paclitaxel plus docetaxel for patients with advanced esophageal cancer.
These authors' data show that adenocarcinoma spreads quickly. This data has a strong implication on the timing of possible clinical trials for patients with adenocarcinoma. If clinical trials will be in the early stage, they may not provide the patients enough clinical benefit to improve survival. This research implies that clinical trials should be conducted at a later stage of adenocarcinoma progression to prevent wasting time on trials where benefit is marginal.
Women who had a first-degree first-degree relative with colorectal adenocarcinoma have lower risk of developing adenocarcinoma in another organ. This may suggest that colorectal cancer predisposes women to developing adenocarcinoma of another organ. Higher percentage of MSS tumors and younger age at diagnosis also had a shorter time to developing adenocarcinoma.
The most common side effects of systemic chemotherapy among cancer patients receiving treatment in one of Denmark's outpatient clinics were diarrhea and nausea. Less frequent side effects were constipation and rash. All side effects were found to be more frequent in patients who received adjuvant chemotherapy than in treatment-naïve patients.